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The question of whether phytoestrogens and
synthetic estrogens are toxicologically similar,
or intrinsically different, presents a challenge to
all involved in human hazard and risk assess-
ments. Although there is a general concern
that exposure to nanogram or microgram
amounts of environmental estrogens may be
associated with adverse health effects, in the
public mind there is a widespread belief that
foods and dietary supplements containing mil-
ligram quantities of phytoestrogens confer only
health beneﬁts. An implicit distinction there-
fore seems to have been drawn between syn-
thetic and plant-derived estrogens—a belief
sustained in the public mind by the assump-
tion that natural is good and synthetic is
bad—but an untested and potentially mislead-
ing notion for those involved with science-
based human hazard/risk assessments.
Phytoestrogens and synthetic estrogens are
generally considered separately in the literature.
For example, Howdeshell et al. (1999) sug-
gested a possible association between the
advance in ﬁrst estrus observed in mice exposed
in utero to 2.4 µg/kg of the synthetic environ-
mental estrogen bisphenol A and reports of an
increased incidence of hypospadias in boys
(Paulozzi et al. 1997) and the earlier sexual
maturation of girls (Herman-Giddens et al.
1997)—the implication being that synthetic
estrogens present a greater hazard than the
much higher levels of phytoestrogens being
consumed by those same children. In contrast,
there are reports of an increased incidence of
hypospadias in boys born to vegetarians (North
and Golding 2000), of alterations in the men-
strual cycle (Cassidy et al. 1994), and of
reduced breast cancer incidences (Messina
1999) among women eating diets rich in
phytoestrogens. Support for these epidemio-
logic observations comes from experimental
studies indicating that advances in sexual
development in rodents can be induced by
their exposure to phytoestrogens (Casanova
et al. 1999; Cassidy and Faughnan 2000; Safe
et al. 2002). In contrast to these separate lines
of inquiry, Newbold and colleagues have evalu-
ated potential similarities between natural and
synthetic estrogens. In seminal studies, they
demonstrated that neonatal exposure of female
mice to equipotent uterotrophic doses of the
phytoestrogen genistein (GEN; Figure 1) or the
synthetic estrogen diethylstilbestrol (DES) leads
to an identical incidence of uterine adenomas at
18 months of age (Newbold et al. 2001).
However, in attempting to draw parallels, or
distinctions, between phytoestrogens and syn-
thetic estrogens, it is imperative to consider
growing awareness of the complexity of estro-
gen signaling pathway and the pleuripotential
biologic activities of most organic chemicals—
irrespective of their origin.
Estrogen signaling in mammalian cells is
primarily mediated at the molecular level by
two members of the nuclear receptor super-
family—estrogen receptors alpha (ER-α) and
beta (ER-β). Ligand-activated ER-α and ER-β
function as transcription factors, in conjunc-
tion with numerous coregulatory proteins, in
order to activate or repress the transcription of
ER-responsive genes (Hall et al. 2001; Moggs
and Orphanides 2001). There is considerable
variation in the binding afﬁnity of ER-α and
ER-β among different estrogens (Kuiper et al.
1998). In the case of the chemicals studied
here, the physiologic estrogen 17β-estradiol
(E2) and DES bind with a similar afﬁnity to
ER-α and ER-β, whereas GEN binds with
approximately 20-fold higher afﬁnity to ER-β
than to ER-α (Kuiper et al. 1998). Concerning
nonhormonal properties of the test chemicals
(most of which have only be deﬁned in vitro),
GEN inhibits a range of enzymes, including
tyrosine kinases (Akiyama et al. 1987), nitric
oxide synthase (Duarte et al. 1997), and topo-
isomerase II (Okura et al. 1988), and also
decreases calcium-channel activity (Potier and
Rovira 1999), lipid peroxidation (Arora et al.
1998), and diacylglycerol synthesis (Dean
et al. 1989). Likewise, DES is reported to
induce aneuploidy in mammalian cells
(Aardema et al. 1998) and to bind to rat liver
DNA (Williams et al. 1993). More recently,
some phytoestrogens were reported to inhibit
the aromatase-mediated conversion of testos-
terone to E2 in vitro (Almstrup et al. 2002),
and equol, the major circulating estrogenic
metabolite associated with the dietary inges-
tion of phytoestrogens, is reported to selec-
tively sequester dihydrotestosterone and
thereby to act as a functional antiandrogen
in vivo (Lund et al. 2004).
In order to advance understanding in this
area, we decided to compare the genes
expressed in the immature mouse uterus
when it had grown in response to treatment
with the estrogens E2, DES, and GEN. The
immature mouse uterus was selected for our
analysis because it is a major estrogen-respon-
sive organ and forms the basis for a reference
assay of estrogenic activity (Owens and Ashby
2002), including carcinogenesis (Newbold
et al. 2001). Furthermore, it expresses both
ER-α and ER-β (Weihua et al. 2000) and the
androgen receptor (Frasor et al. 2003). We
initially conducted a global analysis of gene
expression in the mouse uterus at 1, 2, 4, 8,
24, 48, and 72 hr after exposure to a single
high dose of either GEN (250 mg/kg) or E2
(400 µg/kg). These single high doses yielded a
sustained uterotrophic response over 72 hr
(Figure 2A) and were selected to avoid the
complex transcriptional program that may
result from the standard uterotrophic assay
exposure regime in which each test com-
pound is dosed by repeated administration on
3 consecutive days (Odum et al. 1997).
Groups of 10 sexually immature mice
[Alpk:APfCD-1; 19/20 days of age; main-
tained on RM1 diet (Special Diets Services
Ltd., Witham, Essex, UK)] received a single
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We used gene expression proﬁling to investigate whether the molecular effects induced by estrogens
of different provenance are intrinsically similar. In this article we show that the physiologic estrogen
17β-estradiol, the phytoestrogen genistein, and the synthetic estrogen diethylstilbestrol alter the
expression of the same 179 genes in the intact immature mouse uterus under conditions where each
chemical has produced an equivalent gravimetric and histologic uterotrophic effect, using the
standard 3-day assay protocol. Data are also presented indicating the limitations associated with
comparison of gene expression proﬁles for different chemicals at times before the uterotrophic effects
are fully realized. We conclude that the case has yet to be made for regarding synthetic estrogens as
presenting a unique human hazard compared with phytoestrogens and physiologic estrogens. Key
words: diethylstilbestrol, estrogen, gene expression, genistein, microarray, phytoestrogen, toxico-
genomics, uterus. Environ Health Perspect 112:1137–1142 (2004). doi:10.1289/ehp.7028 available
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Research Commentarysubcutaneous injection of each compound or
the test vehicle [arachis oil (AO); 5 mL/kg], and
uterine RNA was isolated and pooled by group
at each of the seven time points to determine
gene expression levels among the 12,488 mouse
genes represented on the Affymetrix MG-
U74Av2 GeneChip (Affymetrix, High
Wycombe, UK). Transcript proﬁling was per-
formed using MG-U74Av2 GeneChip and
Microarray Analysis Suite 5.0 (Affymetrix).
Normalization and hierarchical clustering were
performed with GeneSpring 6.0 (Silicon
Genetics, Redwood City, CA, USA). MIAME
(Minimum Information About a Microarray
Experiment)-compliant microarray data are
available as supplementary information and
submitted to the Gene Expression Omnibus
(GEO) database (GEO 2004). These data were
analyzed using unsupervised hierarchical clus-
tering and yielded temporal relationships
between the expression proﬁles of 3,450 genes
that were either up- or down-regulated
(> 1.5-fold) by E2 and/or GEN (Figure 2B).
Each chemical induced a similar, multistage
transcriptional response (Figure 2B), although
it is noteworthy that we observed variations in
the magnitude and timing of both early (e.g.,
c-fos) and late (e.g., lactotransferrin) ER-respon-
sive genes during the uterotrophic responses
induced by E2 and GEN (Figure 2C). 
A detailed description of the molecular
functions of the genes affected, together with
their association with physiologic changes dur-
ing uterine growth, has been reported
(Orphanides et al. 2003) and will be described
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Figure 1. Chemical structure of GEN, E2, and DES.
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Figure 2. Induction of very similar multistage transcriptional responses in the mouse uterus by E2 and GEN.
(A) Blotted uterine weights (mean ± SD) of sexually immature mice (n = 10/group) at different times after a
single subcutaneous dose of E2 (400 µg/kg), GEN (250 mg/kg), or AO (control; 5 mL/kg). See text for details
of experiments. (B) Temporal expression proﬁles of 3,450 genes up-regulated or repressed (> 1.5-fold) by
either E2 (400 µg/kg) or GEN (250 mg/kg) at one or more of seven different time points. The magnitude of
altered gene expression (fold change vs. time-matched vehicle control) is indicated by color; genes are
grouped according to similarity of their temporal expression proﬁles (Pearson correlation-based hierarchi-
cal clustering). (C) Northern blot analysis of temporal expression pattern of early (c-fos) and late (lacto-
transferrin) estrogen-responsive genes; the fold induction of gene expression relative to time-matched
vehicle controls was calculated after data were normalized to the expression of the control gene RPB1
(accession number NM_009089).
*p < 0.05; **p < 0.01; two-sided Student t-test. 
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Figure 3. Equivalence of biologic responses induced
in the mouse uterus by E2 (E), GEN (G), and DES (D).
(A) Blotted uterine weights (mean ± SD) of three
independent replicate groups (1–3) of sexually imma-
ture mice (n = 4/group) after three daily subcuta-
neous injections of either GEN (50 mg/kg), E2
(2.5 µg/kg), DES (2 µg/kg), or AO [control (C); 5 mL/kg].
(B) Unsupervised Euclidean-distance–based hier-
archical clustering of 4,134 expressed genes. (C)
Near-identical gene expression proﬁles induced by
the three estrogens 72 hr after equipotent
uterotrophic doses. Significant changes in gene
expression induced by one or more of the three
estrogens were identiﬁed by one-way ANOVA (para-
metric test, assuming equal variance). The magni-
tude of altered gene expression (fold change vs.
vehicle control) is indicated by color.in more detail in a future publication (Moggs
et al., unpublished data). 
These observations suggest that GEN does
not induce “off-target” ER-independent tran-
scriptional responses, that is, those associated
with the properties of GEN other than estro-
genicity. Furthermore, there was no evidence
for the topoisomerase II–inhibiting properties
of GEN in the bone marrow of the present
mice despite demonstration of the sensitivity of
that tissue to the potent micronucleus-induc-
ing activity of the topoisomerase II inhibitor
etoposide (data not shown). Together, these
data led us to question whether a synthetic
estrogen such as DES would also induce simi-
lar transcriptional responses in the immature
mouse uterus. 
In order to avoid temporal vagaries in gene
expression (e.g., Figure 2C), we decided to
anchor our transcript profiling data to the
phenotype of the grown uterus by employing
equipotent uterotrophic doses of E2, GEN,
and DES. We compared the global gene
expression proﬁles in the uteri of intact imma-
ture mice stimulated with three daily low
doses of either GEN, DES, or E2, with an
exposure regimen the same as that used in a
standard 3-day uterotrophic assay (Odum
et al. 1997). The route of administration and
the doses of GEN and DES used were as
described by Newbold et al. (2001) in their
equivalent-outcome carcinogenicity bioassays
of these two chemicals. Three independent
replicates of four groups of sexually immature
mice (Alpk:APfCD-1; 19/20 days of age;
maintained on RM1 diet) received three daily
subcutaneous injections of GEN (50 mg/kg),
E2 (2.5 µg/kg), or DES (2 µg/kg). Control
animals received the vehicle, AO (5 mL/kg).
These doses elicited similar uterotrophic
responses (72 hr after the initial dose;
Figure 3A, Table 1) and identical histologic
changes in the uteri of the treated animals
(Table 1). Uterine RNA was isolated and
pooled for each of the 12 groups and analyzed
for changes in gene expression levels using the
same Affymetrix microarray of 12,488 mouse
genes. The data were analyzed using two inde-
pendent statistical methods. First, unsuper-
vised hierarchical clustering deﬁned the global
relationships (Euclidean distances) between
the 12 gene expression profiles (Figure 3B).
The three control groups clustered under one
node, whereas the chemical treatment groups
formed a separate node of compound-
independent clusters, indicating equal similarity
within and between the transcriptional
responses induced by the three estrogens
(Figure 3B). One-way analysis of variance
(ANOVA), with Bonferroni (Holm 1979)
correction (familywise error rate < 0.05) to
minimize false positives, identiﬁed 179 genes
where expression levels were altered by one or
more chemical treatments (Figure 3C).
Remarkably, Tukey post hoc testing revealed
that all of these genes were affected in all nine
compound treatment groups. 
Table 2 highlights the high degree of simi-
larity between the transcriptional responses to
each of the three estrogens. These include
established estrogen-responsive genes such as
lactotransferrin, complement component 3,
c-fos, small proline-rich protein 2A, and kerato-
epithelin (Hewitt et al. 2003; Naciff et al.
2003), together with many genes that have not
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Table 1. Blotted uterine weights and endometrial and epithelial cell heights (mean ± SD) after exposure to
E2, GEN, or DES for 3 consecutive days.a
Dose Blotted uterine weight Cell height (µm)
Compound (per kg) (mg) Endometrium Epithelium
AO 5 mL 13.0 ± 2.4 159.0 ± 23.1 (11) 11.4 ± 1.1
E2 2.5 µg 45.3 ± 8.6* 246.1 ± 52.4* (9) 23.3 ± 1.4*
GEN 50 mg 39.8 ± 5.3* 273.7 ± 63.3* (12) 23.7 ± 3.1*
DES 2.0 µg 49.8 ± 13.0* 273.2 ± 55.9* (10) 22.6 ± 4.0*
There were 12 animals/group, but not all of the histopathology samples were suitable for analyses; numbers in parentheses
indicate the number of animals per group from which the histology data were generated.
aData were assessed for statistical signiﬁcance using a two-sided Student t-test: *p < 0.01.
Table 2. Quantitative data for 179 differentially expressed genes (from Figure 3C) regulated in the mouse uterus by all three estrogens (E2, GEN, and DES).a
Fold change in Fold change in
GenBank expression (mean ± SD) GenBank expression (mean ± SD)
Gene name accession no. E2 GEN DES Gene name accession no. E2 GEN DES
Continued, next page
Up-regulated genes
Solute carrier family 9a3r1 U74079 1.8 ± 0.01 2.0 ± 0.1 2.0 ± 0.2
Keratin complex 2–8 X15662 2.6 ± 0.2 3.1 ± 0.2 3.1 ± 0.3
Laminin beta 3 U43298 4.3 ± 0.1 5.5 ± 1.1 5.3 ± 0.7
Claudin 7 AF087825 4.5 ± 0.5 6.5 ± 1.0 5.8 ± 0.6
bHLH-Zip transcription factor U49507 2.6 ± 0.3 3.1 ± 0.3 2.9 ± 0.1
RIKEN cDNA 1200008D14 AW208938 3.0 ± 0.3 3.5 ± 0.1 3.3 ± 0.3
Basic HLH-domain containing, Y07836 5.9 ± 1.0 6.6 ± 0.9 6.6 ± 0.8
class B2
RIKEN cDNA 9930104H07 AW122310 3.0 ± 0.3 3.2 ± 0.4 3.3 ± 0.1
Fucosyltransferase 2 AF064792 27.5 ± 1.2 34.6 ± 8.5 36.7 ± 5.5
Deleted in polyposis 1 U28168 1.8 ± 0.1 2.0 ± 0.02 2.0 ± 0.1
Microsomal glutathione AI843448 2.9 ± 0.2 3.3 ± 0.6 3.3 ± 0.1
S-transferase 3
Tumor-associated Ca signal Y08830 4.0 ± 0.3 4.6 ± 0.9 4.6 ± 0.3
transducer 2
Calpain 5 Y10656 5.5 ± 0.4 6.3 ± 1.0 6.6 ± 0.6
Mitochondrial creatine kinase Z13969 9.7 ± 1.1 12.2 ± 2.1 13.1 ± 1.8
ATPase 6v1a1 AW123765 2.0 ± 0.1 2.1 ± 0.2 2.1 ± 0.2
Tumor-associated Ca signal AI563854 8.0 ± 0.4 9.2 ± 1.0 8.5 ± 0.4
transducer 2
Lymphocyte antigen 6 complex, X04653 7.8 ± 0.9 8.8 ± 0.3 8.5 ± 0.4
locus A
Chloride channel calcium- AV373378 26.4 ± 3.4 26.7 ± 1.0 26.2 ± 3.9
activated 3
Small proline-rich protein 2I AJ005567 23.9 ± 1.5 24.7 ± 1.3 23.6 ± 1.6
Oncoprotein induced transcript 1 AA615075 19.0 ± 3.1 20.0 ± 1.2 18.9 ± 2.5
Small proline-rich protein 2F AJ005564 59.8 ± 8.4 65.8 ± 1.1 60.6 ± 2.6
Small proline-rich protein 2E AJ005563 12.0 ± 1.0 12.9 ± 0.8 12.1 ± 0.9
Mucin 1 M84683 8.3 ± 0.6 8.6 ± 0.3 8.5 ± 0.5
Lipoocalin 2 X81627 150.3 ± 15.0 175.7 ± 10.5 162.8 ± 6.5
RIKEN cDNA 2210409B01 AF109906 3.5 ± 0.6 4.0 ± 0.3 3.8 ± 0.8
Interferon-activated gene 202A M31418 7.9 ± 1.0 9.8 ± 2.5 8.8 ± 0.7
Nuclear ankyrin-repeat protein AA614971 3.7 ± 0.6 4.3 ± 0.7 4.1 ± 0.9
RIKEN cDNA 5730469M10 AI850090 22.0 ± 5.8 30.5 ± 9.1 27.0 ± 6.5
RIKEN cDNA 1110034C02 AI837104 1.5 ± 0.1 1.6 ± 0.1 1.6 ± 0.03
IMAGE cDNA 4988271 AV373294 8.0 ± 2.5 10.6 ± 1.6 9.2 ± 1.1
RIKEN cDNA 5730493B19 AW122413 12.7 ± 0.3 19.0 ± 4.1 15.7 ± 0.9
Peptidoglycan recognition AV092014 13.4 ± 1.5 18.3 ± 3.0 14.5 ± 2.1
protein
Inhibin beta-B X69620 13.6 ± 3.1 19.4 ± 4.7 16.0 ± 1.4
CEA-related cell adhesion AF101164 11.9 ± 1.6 17.8 ± 5.3 14.2 ± 1.7
molecule 2
Keratin complex 1–19 M36120 4.4 ± 0.4 5.5 ± 1.1 4.8 ± 0.5
CEA-related cell adhesion M77196 15.9 ± 2.4 23.9 ± 5.9 19.0 ± 3.8
molecule 1
SRC family-associated AB014485 2.7 ± 0.04 3.2 ± 0.4 2.9 ± 0.3
phosphoprotein 2
Peptidoglycan recognition AF076482 7.7 ± 1.9 10.4 ± 2.7 9.0 ± 2.0
protein
CEA-related cell adhesion M77196 19.5 ± 3.9 30.4 ± 8.8 22.2 ± 2.7
molecule 1previously been associated with estrogenicity
(Table 2).
Although these three estrogens can alter the
expression of some genes with different magni-
tudes [e.g., peptidyl arginine deiminase II is
up-regulated to a lesser extent by E2 (1.86-fold
± 0.27) relative to GEN (9.11-fold ± 0.33) and
DES (5.15-fold ± 1.53); Table 2], the present
data show that the same genes are affected dur-
ing equivalent uterotrophic responses. Previous
studies have revealed both similarities and dif-
ferences between transcriptional responses
induced at a single time point after exposure to
E2 and DES in the uteri of immature ovari-
ectomized mice (Watanabe et al. 2003) and
after exposure to either GEN, bisphenol A, or
17α-ethynyl estradiol in the reproductive tract
of intact adult rats (Naciff et al. 2002). We sug-
gest that these reported differences most proba-
bly arise from dose-dependent variations in the
magnitude and kinetics of gene expression
(Figure 2C), rather than from the operation of
distinct mechanisms of estrogenic action.
Our data indicate that estrogens of differ-
ing provenance may have in common the
potential for both beneficial and adverse
health effects. This highlights the need for an
holistic approach to hazard assessment
wherein preconceptions are replaced by an
objective assessment of the likely perturbations
of physiologic functions caused by combined
exposures to physiologic, synthetic, and plant-
derived estrogens. This need is reinforced by
data showing that plasma concentrations of
isoflavones in infants fed soy formula are
approximately 200 times higher than for those
fed human milk (Setchell et al. 1997), by the
estimated daily intake of approximately 29 mg
of phytoestrogens for individuals taking
dietary supplements (Committee on Toxicity
of Chemicals in Food, Consumer Products
and the Environment 2003), and by the
demonstration that estrogens of different
provenance can act additively in the rodent
uterus (Tinwell and Ashby 2004).
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Table 2. Continued
Fold change in Fold change in
GenBank expression (mean ± SD) GenBank expression (mean ± SD)
Gene name accession no. E2 GEN DES Gene name accession no. E2 GEN DES
Continued, next page
CEA-related cell adhesion X67279 6.4 ± 0.7 8.4 ± 1.1 7.1 ± 1.1
molecule 1
Spermidine N1-acetyl L10244 8.3 ± 0.9 11.2 ± 0.8 9.3 ± 0.6
transferase
RIKEN cDNA 0610007O07 AI851762 2.7 ± 0.1 3.0 ± 0.3 2.8 ± 0.1
Arginase 1 U51805 79.4 ± 9.8 131.9 ± 20.0 99.6 ± 14.5
Acetyl-coenzyme A
synthetase 2 AW125884 2.2 ± 0.2 2.0 ± 0.1 2.2 ± 0.2
v-erb-b2 homolog 3 AI006228 3.4 ± 0.4 3.1 ± 0.6 3.4 ± 0.4
Phospholipase D3 AF026124 2.6 ± 0.2 2.4 ± 0.2 2.6 ± 0.2
RIKEN cDNA 0610031J06 AW122935 1.9 ± 0.1 1.8 ± 0.1 1.8 ± 0.1
Complement component 1q X58861 2.1 ± 0.1 2.0 ± 0.1 2.0 ± 0.2
Scotin AW123754 2.0 ± 0.1 2.0 ± 0.2 2.0 ± 0.2
CD24a antigen M58661 3.2 ± 0.1 3.1 ± 0.1 3.3 ± 0.3
Argininosuccinate synthetase 1 M31690 2.7 ± 0.3 2.7 ± 0.3 2.8 ± 0.4
ATPase 6v1a1 U13837 2.1 ± 0.1 2.1 ± 0.2 2.2 ± 0.2
Gelsolin-like actin-capping X54511 3.6 ± 0.5 3.7 ± 0.5 3.7 ± 0.2
protein
Golgi phosphoprotein 2 AW125446 4.5 ± 0.5 4.6 ± 0.5 4.7 ± 0.1
Aldolase 1A Y00516 2.3 ± 0.2 2.3 ± 0.1 2.4 ± 0.1
Cathepsin L X06086 6.4 ± 0.8 6.3 ± 1.1 6.9 ± 0.4
CD14 antigen X13333 3.0 ± 0.1 2.8 ± 0.1 3.1 ± 0.2
Decay accelerating factor 2 L41365 4.0 ± 0.1 3.8 ± 0.8 3.8 ± 0.2
Actin-related protein AW212775 2.1 ± 0.2 2.1 ± 0.1 2.1 ± 0.2
2/3 complex 1B
Protective protein for J05261 2.0 ± 0.1 2.0± 0.1 2.0 ± 0.1
β-galactosidase
Elastase 1 M27347 2.7 ± 0.1 2.5 ± 0.2 2.6 ± 0.1
Connexin 26 M81445 10.6 ± 1.0 9.8 ± 0.5 10.4 ± 0.8
Ceruloplasmin U49430 15.1 ± 2.8 15.0 ± 5.5 14.5 ± 2.1
Cathepsin H U06119 3.0 ± 0.2 3.0 ± 0.3 3.0 ± 0.3
Basigin Y16258 1.6 ± 0.1 1.5 ± 0.1 1.7 ± 0.1
Peptidylprolyl isomerase X67809 2.2 ± 0.2 2.2 ± 0.1 2.4 ± 0.3
C–associated
Glutathione reductase 1 AI851983 2.3 ± 0.2 2.3 ± 0.1 2.6 ± 0.3
START domain–containing 3 X82457 1.5 ± 0.1 1.4 ± 0.03 1.5 ± 0.01
CD68 antigen X68273 4.6 ± 0.6 4.2 ± 0.6 5.0 ± 0.7
RIKEN cDNA E030027H19 AW211760 2.7 ± 0.3 2.7 ± 0.2 2.9 ± 0.1
cDNA sequence BC004044 AI461767 3.1 ± 0.2 3.4 ± 0.1 3.8 ± 0.5
E74-like factor 3 AF016294 5.1 ± 0.8 5.9 ± 0.5 6.5 ± 0.5
Glutathione S-transferase AI843119 5.0 ± 1.1 4.6 ± 0.6 4.1 ± 0.7
omega 1
Interferon-stimulated protein 20 AW122677 4.2 ± 0.1 4.3 ± 0.7 3.4 ± 0.4
Clusterin D14077 3.6 ± 0.7 3.9 ± 0.9 3.4 ± 0.4
Galectin 3 X16834 7.4 ± 1.3 8.7 ± 0.7 6.9 ± 0.4
Small proline-rich protein 2Ab AJ005559 51.1 ± 4.0 78.3 ± 15.7 44.2 ± 5.2
Complement component 3b K02782 14.8 ± 1.8 18.8 ± 1.0 14.8 ± 0.8
Small proline-rich protein 2C AJ005561 220.3± 31.0 340.5 ± 37.1 214.1 ± 41.1
Small proline-rich protein 2G AJ005565 9.4 ± 0.9 11.0 ± 0.3 9.6 ± 0.6
Prominin AF039663 3.5 ± 0.5 3.6 ± 0.6 3.4 ± 0.3
Lactotransferrinb J03298 88.7 ± 18.4 99.2 ± 13.9 76.9 ± 21.8
Carbonic anhydrase 2 M25944 7.9 ± 0.5 8.2 ± 0.9 7.3 ± 0.4
Complement component U47810 36.5 ± 4.4 38.4 ± 5.6 32.9 ± 4.2
factor I
Mannosidase 2alphaB1 U87240 2.0 ± 0.2 2.0 ± 0.1 1.9 ± 0.1
Small proline-rich protein 2B AJ005560 32.9 ± 3.7 39.2 ± 1.9 30.7 ± 5.0
Small proline-rich protein 2Ab AJ005559 269.8 ± 23.7 329.1 ± 42.9 59.1 ± 40.8
RIKEN cDNA 5830413E08 AI849939 3.3 ± 0.4 3.3 ± 0.5 3.0 ± 0.3
RIKEN cDNA 1110029F20 AW125508 4.1 ± 0.1 4.1 ± 0.4 3.7 ± 0.1
Annexin A3 AJ001633 2.7 ± 0.5 4.2 ± 0.7 3.2 ± 0.6
Peptidase 4 U51014 2.0 ± 0.1 2.9 ± 0.3 2.3 ± 0.2
Laminin gamma 2 U43327 6.3 ± 1.3 17.3 ± 6.8 10.2 ± 1.0
Ubiquitin-like 3 AW120725 1.5 ± 0.1 1.8 ± 0.1 1.7 ± 0.03
Urate oxidase M27695 23.8 ± 9.5 143.9 ± 62.9 43.8 ±17.7
Amiloride binding protein 1 AI197481 3.5 ± 1.0 10.1 ± 0.8 6.0 ± 1.2
Keratin complex 1–19 AU040563 4.5 ± 1.0 7.2 ± 1.0 5.6 ± 0.4
Activated leukocyte cell L25274 3.6 ± 0.8 5.1 ± 0.9 4.4 ± 0.5
adhesion molecule
CCAAT/enhancer binding M61007 2.3 ± 0.1 2.8 ± 0.3 2.6 ± 0.1
protein β
Peptidyl arginine deiminase, AB013848 8.6 ± 0.7 15.8 ± 3.1 12.0 ± 1.7
type I
Enolase 1 α AI841389 2.5 ± 0.3 3.2 ± 0.5 3.0 ± 0.3
p53 apoptosis effector related AI854029 2.9 ± 0.3 4.1 ± 0.8 3.7 ± 0.5
to Pmp22
β-Glucuronidase M19279 1.9 ± 0.1 2.3 ± 0.2 2.2 ± 0.1
Leucine-rich AW230891 9.3 ± 1.1 17.6 ± 4.1 14.5 ± 2.6
α-2-glycoprotein
Quiescin Q6 AW123556 3.7 ± 0.2 5.5 ± 1.2 4.8 ± 0.7
GADD45a U00937 1.9 ± 0.2 2.6 ± 0.3 2.3 ± 0.1
Alkaline phosphatase 2 J02980 9.2 ± 0.4 22.6 ± 6.2 15.8 ± 2.0
Immediate early response 3 X67644 5.5 ± 0.8 10.8 ± 2.2 8.9 ± 2.0
Progressive ankylosis AW049351 2.2 ± 0.1 2.9 ± 0.4 2.8 ± 0.4
RAS p21 protein activator 4 AA163960 6.8 ± 0.9 14.2 ± 2.5 12.1 ± 1.7
Tumor-associated calcium M76124 2.1 ± 0.2 2.7 ± 0.3 2.6 ± 0.2
signal transducer 1
Hydroxysteroid (17-beta) AA822174 1.9 ± 0.1 2.3 ± 0.3 2.4 ± 0.1
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Table 2. Continued
Fold change in Fold change in
GenBank expression (mean ± SD) GenBank expression (mean ± SD)
Gene name accession no. E2 GEN DES Gene name accession no. E2 GEN DES
Abbreviations: CEA, carcinoembrionary antigen; SRC, steroid receptor coactivator; TGF, transforming growth factor.
aGene names (derived from the NetAffx database; Liu et al. 2003), GenBank accession numbers (GenBank 2004), and mean (± SD) fold induction/repression of gene expression are
shown in the same order as the gene cluster in Figure 3C. bGenes mentioned in the text.
Platelet-activating factor U57746 1.9 ± 0.1 2.2 ± 0.2 2.3 ± 0.1
acetylhydrolase 1ba1
Branched chain U42443 2.4 ± 0.2 3.4 ± 0.2 3.4 ± 0.01
aminotransferase 1
RIKEN cDNA 2400004E04 AI846720 1.7 ± 0.1 2.4 ± 0.2 2.3 ± 0.2
Myeloblastosis oncogene M12848 2.8 ± 0.4 5.6 ± 1.1 5.0 ± 0.2
K+ conductance calcium- AF042487 3.1 ± 0.2 4.2 ± 0.6 3.5 ± 0.8
activated channel N4
ATPase 6v1b2 AI843029 1.7 ± 0.1 1.8 ± 0.1 1.8 ± 0.1
Cystic ﬁbrosis transmembrane M60493 3.4 ± 0.5 4.5 ± 0.8 3.9 ± 0.3
regulator
RIKEN cDNA 1110008P14 AI839839 4.3 ± 0.4 6.0 ± 1.0 5.1 ± 0.2
Fused toes Z67963 2.6 ± 0.2 3.2 ± 0.3 2.8 ± 0.1
Solute carrier family 39a8 AW124340 3.5 ± 0.5 4.5 ± 0.7 3.8 ± 0.3
Cytochrome b-561 AI846517 2.2 ± 0.2 2.5 ± 0.2 2.3 ± 0.2
Secreted phosphoprotein 1 X13986 30.2 ± 3.3 47.4 ± 7.4 31.1 ± 2.7
Ion transport regulator Fxyd3 X93038 5.3 ± 0.4 6.8 ± 1.1 5.5 ± 0.6
Janus kinase 3 L40172 2.1 ± 0.2 2.5 ± 0.2 2.2 ± 0.2
Cytochrome b-245alpha AW046124 2.9 ± 0.4 3.6 ± 0.4 2.9 ± 0.2
RIKEN cDNA A430096B05 AI465965 6.3 ± 1.0 8.6 ± 0.03 6.3 ± 0.6
Small proline-rich protein 2J AJ005568 8.6 ± 2.1 13.8 ± 3.2 8.5 ± 0.7
Cathepsin B M65270 2.2 ± 0.1 2.6 ± 0.2 2.2 ± 0.1
RIKEN cDNA 1600025H15 AI842734 2.2 ± 0.1 2.7 ± 0.3 2.2 ± 0.2
c-fos oncogeneb V00727 3.2 ± 0.4 4.7 ± 0.9 3.7 ± 0.8
Guanine nucleotide binding AI843937 1.6 ± 0.1 1.8 ± 0.1 1.6 ± 0.03
protein γ5
Serine palmitoyltransferase  U27455 1.6 ± 0.1 2.0 ± 0.2 1.7 ± 0.1
lc2
Cystatin B U59807 1.5 ± 0.1 1.7 ± 0.1 1.5 ± 0.02
Villin 2 X60671 1.9 ± 0.2 2.4 ± 0.3 1.9 ± 01
RIKEN cDNA 0610010O12 AI849011 1.9 ± 0.1 2.5 ± 0.3 1.9 ± 0.03
Matrix metalloproteinase 7 L36244 47.8 ± 18.6 208.6 ± 83.3 48.2 ± 11.9
RIKEN cDNA 4930422J18 AV376312 2.0 ± 0.3 2.9 ± 0.3 2.0 ± 0.2
RIKEN cDNA 1700017B05 AW049360 1.6 ± 0.1 2.0 ± 0.1 1.6 ± 0.1
Galactosidase beta 1 M57734 1.8 ± 0.1 2.0 ± 0.1 1.7 ± 0.1
Cathepsin C U74683 2.6 ± 0.1 3.3 ± 0.2 2.3 ± 0.3
Interferon-stimulated X56602 3.6 ± 0.6 2.0 ± 0.2 3.8 ± 0.7
protein 15
MAP kinase–interacting Y11092 1.8 ± 0.1 1.4 ± 0.1 1.9 ± 0.1
kinase 2
Glutathione S-transferase X98056 3.5 ± 0.4 2.9 ± 0.4 3.6 ± 0.2
theta 2
Homeobox B6 M18401 1.5 ± 0.02 1.5 ± 0.1 1.6 ± 0.03
Procollagen VIalpha 3 AF064749 2.1 ± 0.2 1.9 ± 0.2 2.1 ± 0.02
Interferon regulatory factor 7 U73037 11.7 ± 0.9 8.1 ± 0.7 12.6 ± 1.5
Scavenger receptor class B2 AB008553 2.7 ± 0.1 2.4 ± 0.3 2.6 ± 0.2
Polyimmunoglobulin receptor AB001489 8.1 ± 0.7 6.2 ± 0.8 7.9 ± 1.0
Proteasome subunit β10 Y10875 2.1 ± 0.04 1.9 ± 0.04 2.1 ± 0.1
RIKEN cDNA 0610010E05 AV312736 2.9 ± 0.3 2.5 ± 0.2 2.7 ± 0.4
RIKEN cDNA 0610010E05 AI854839 3.7 ± 0.5 3.0 ± 0.1 3.4 ± 0.3
Xanthine dehydrogenase X75129 12.2 ± 2.2 8.9 ± 1.2 10.1 ± 1.5
Prominin AF039663 3.5 ± 0.2 2.9 ± 0.2 3.1 ± 0.3
Interferon-induced protein U43084 17.5 ± 2.9 9.9 ± 1.5 14.0 ± 2.1
IFIT1
Interferon-induced protein  U43086 8.1 ± 2.3 4.7 ± 0.2 6.7 ± 0.6
IFIT3
Proteasome subunit β8 U22033 2.0 ± 0.1 1.8 ± 0.2 2.1 ± 0.1
RIKEN cDNA 1600023A02 AW121336 1.9 ± 0.1 1.7 ± 0.1 2.0 ± 0.04
Small proline-rich protein 1A AF057156 11.1 ± 3.7 8.6 ± 0.8 14.7 ± 0.8
MAP kinase-interacting AI845732 2.0 ± 0.1 1.7 ± 0.1 2.0 ± 0.2
kinase 2
Lymphocyte antigen 6 complex, U47737 2.0 ± 0.01 1.7 ± 0.1 2.0 ± 0.1
locus E
Guanylate nucleotide binding AJ007970 3.0 ± 0.1 2.0 ± 0.2 2.6 ± 0.1
protein 2
Peptidyl arginine deiminase, D16580 1.9 ± 0.3 9.1 ± 0.3 5.2 ± 1.5
type IIb
Down-regulated genes
Solute carrier family 29a1 AI838274 2.0 ± 0.2 2.9 ± 0.3 2.5 ± 0.1
Lymphocyte speciﬁc 1 D49691 1.6 ± 0.1 2.3 ± 0.2 1.8 ± 0.1
Claudin 5 U82758 2.0 ± 0.2 2.8 ± 0.1 2.7 ± 0.5
Potassium channel td12 AI842065 1.6 ± 0.04 2.0 ± 0.04 2.1 ± 0.1
Zinc ﬁnger homeobox 1a D76432 1.5 ± 0.1 1.7 ± 0.1 1.8 ± 0.01
Monoamine oxidase A AI848045 2.3 ± 0.2 2.7 ± 0.2 2.5 ± 0.4
Histidine decarboxylase X57437 4.8 ± 0.8 7.1 ± 0.6 5.4 ± 0.8
α-2 Adrenergic receptor M97516 3.0 ± 0.3 4.2 ± 1.1 3.6 ± 0.3
Transcription factor 21 AF035717 1.8 ± 0.2 2.2 ± 0.2 2.0 ± 0.1
Homeobox D8 X56561 2.2 ± 0.1 2.8 ± 0.03 2.5 ± 0.2
Carboxypeptidase X2 AF017639 4.1 ± 0.7 5.2 ± 1.0 4.2 ± 0.2
RIKEN cDNA A230106A15 AI848841 3.8 ± 0.2 4.7 ± 0.5 4.2 ± 0.7
Reduced expression 3 AA790008 3.1 ± 0.2 3.5 ± 0.3 3.2 ± 0.4
TGF-β binding protein 4 AA838868 1.8 ± 0.1 2.1 ± 0.1 1.8 ± 0.2
Keratoepithelinb L19932 11.5 ± 2.5 12.6 ± 0.9 9.7 ± 3.6
GLI-Kruppel family member GLI AB025922 11.6 ± 0.8 12.2 ± 2.6 8.2 ± 2.6Hewitt SC, Deroo BJ, Hansen K, Collins J, Grissom S, Afshari CA,
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